Subsequent knock-in or overexpression of PRODH2-the leading target, enhanced the killing effect and in vivo efficacy of CAR-T in many cancer models, probably due to the transcriptomics and metabonomics broadly reshaped in PRODH2 high expressioned CAR-T cells (Ye et al., 2022). The gene discussed is PRODH2; the disease is cancer.